Hassan Albadawi1, Rahmi Oklu2, Rita Elise Raacke Malley3, Ryan M O'Keefe3, Thuy P Uong3, Nicholas R Cormier3, Michael T Watkins4. 1. Department of Surgery, Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: halbadawi@partners.org. 2. Department of Radiology, Division of Vascular Imaging and Intervention, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. 3. Department of Surgery, Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass. 4. Department of Surgery, Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Abstract
OBJECTIVE: Extracellular traps (ETs) consisting of DNA-protein complexes formed after tissue injury contribute to the inflammatory and thrombosis cascades, thereby exacerbating injury. Exogenous DNase I has been suggested as a therapeutic strategy to limit injury in the brain and myocardium. These studies were designed to evaluate the effects of exogenous DNase I treatment on skeletal muscle injury after acute hindlimb ischemia-reperfusion (IR) injury in mice and to determine whether neutrophils are a major source of ETs in postischemic muscle tissue. METHODS: C57BL6 mice were subjected to 1.5 hours of tourniquet ischemia and 24 hours of reperfusion with and without human recombinant DNase I treatment. A separate set of mice was subjected to neutrophil depletion (ND), followed by the same intervals of IR. Laser Doppler imaging and tissue harvesting were done at 24 hours for assessment of limb perfusion, muscle fiber injury, adenosine triphosphate (ATP) level, markers of inflammation, thrombosis, and formation of ETs. RESULTS: DNase I treatment significantly reduced detection of ETs in postischemic muscle but did not alter skeletal muscle fiber injury, levels of proinflammatory molecules, or ATP level. DNase I treatment did enhance postischemic hindlimb perfusion, decreased infiltrating inflammatory cells, and reduced the expression of thrombin-antithrombin III. ND resulted in a significant yet small reduction in ETs in the postischemic muscle. ND did not alter skeletal muscle fiber injury, hindlimb perfusion, or ATP levels. CONCLUSIONS: These data suggest that neither DNase I treatment nor ND was protective against IR injury, even though both decreased detection of ETs in skeletal muscle after IR. Neutrophils are not the only source of ETs after IR.
OBJECTIVE: Extracellular traps (ETs) consisting of DNA-protein complexes formed after tissue injury contribute to the inflammatory and thrombosis cascades, thereby exacerbating injury. Exogenous DNase I has been suggested as a therapeutic strategy to limit injury in the brain and myocardium. These studies were designed to evaluate the effects of exogenous DNase I treatment on skeletal muscle injury after acute hindlimb ischemia-reperfusion (IR) injury in mice and to determine whether neutrophils are a major source of ETs in postischemic muscle tissue. METHODS: C57BL6 mice were subjected to 1.5 hours of tourniquet ischemia and 24 hours of reperfusion with and without human recombinant DNase I treatment. A separate set of mice was subjected to neutrophil depletion (ND), followed by the same intervals of IR. Laser Doppler imaging and tissue harvesting were done at 24 hours for assessment of limb perfusion, muscle fiber injury, adenosine triphosphate (ATP) level, markers of inflammation, thrombosis, and formation of ETs. RESULTS:DNase I treatment significantly reduced detection of ETs in postischemic muscle but did not alter skeletal muscle fiber injury, levels of proinflammatory molecules, or ATP level. DNase I treatment did enhance postischemic hindlimb perfusion, decreased infiltrating inflammatory cells, and reduced the expression of thrombin-antithrombin III. ND resulted in a significant yet small reduction in ETs in the postischemic muscle. ND did not alter skeletal muscle fiber injury, hindlimb perfusion, or ATP levels. CONCLUSIONS: These data suggest that neither DNase I treatment nor ND was protective against IR injury, even though both decreased detection of ETs in skeletal muscle after IR. Neutrophils are not the only source of ETs after IR.
Authors: Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner Journal: Blood Date: 2013-11-07 Impact factor: 22.113
Authors: Ramanjaneyulu Allam; Santhosh V R Kumar; Murthy N Darisipudi; Hans-Joachim Anders Journal: J Mol Med (Berl) Date: 2014-04-06 Impact factor: 4.599
Authors: A S Savchenko; K Martinod; M A Seidman; S L Wong; J I Borissoff; G Piazza; P Libby; S Z Goldhaber; R N Mitchell; D D Wagner Journal: J Thromb Haemost Date: 2014-06 Impact factor: 5.824
Authors: A Brill; T A Fuchs; A S Savchenko; G M Thomas; K Martinod; S F De Meyer; A A Bhandari; Denisa D Wagner Journal: J Thromb Haemost Date: 2012-01 Impact factor: 5.824
Authors: Julian I Borissoff; Ivo A Joosen; Mathijs O Versteylen; Alexander Brill; Tobias A Fuchs; Alexander S Savchenko; Maureen Gallant; Kimberly Martinod; Hugo Ten Cate; Leonard Hofstra; Harry J Crijns; Denisa D Wagner; Bas L J H Kietselaer Journal: Arterioscler Thromb Vasc Biol Date: 2013-07-01 Impact factor: 8.311
Authors: Nicole J Edwards; Charles Hwang; Simone Marini; Chase A Pagani; Philip J Spreadborough; Cassie J Rowe; Pauline Yu; Annie Mei; Noelle Visser; Shuli Li; Geoffrey E Hespe; Amanda K Huber; Amy L Strong; Miriam A Shelef; Jason S Knight; Thomas A Davis; Benjamin Levi Journal: FASEB J Date: 2020-10-22 Impact factor: 5.191
Authors: Ľ Janovičová; B Gromová; D Drobná; B Konečná; E Renczés; V Borbélyová; J Hodosy; P Celec Journal: Physiol Res Date: 2021-10-30 Impact factor: 1.881